Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01760993

Enrollment

Registered

2013-01-04

Start date

2013-02-01

Completion date

2013-04-01

Last updated

2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Not Required

Brief summary

The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.

Detailed description

Not required

Interventions

DRUGSPD489

Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 18 to 65 years of age * Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends \>4 hours/week with the subject) * Fixed home/place of residence and can be reached by telephone * On a stable dose of antipsychotic medications * Able to swallow capsules

Exclusion criteria

* -Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products * Treated with clozapine in past 30 days * Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence * History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions * Uncontrolled hypertension * History of thyroid disorder that has not been stabilized on thyroid medication * Glaucoma * Pregnant or nursing * Subject has received an investigational product or participated in a clinical study within 30 days

Design outcomes

Primary

Measure	Time frame
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks	Baseline and 52 weeks
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks	Basline and 52 weeks
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks	Baseline and 52 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)	Up to 52 weeks

Secondary

Measure	Time frame
Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks	Baseline and 52 weeks
Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale	Baseline and week 52
Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale	Up to 52 weeks
Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks	Baseline and 52 weeks
Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks	Baseline and 52 weeks

Countries

United States

Participant flow

Pre-assignment details

Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized

Participants by arm

Arm	Count
SPD489 SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks	0
Total	0

Baseline characteristics

Characteristic	—
Region of Enrollment United States	—

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 0
serious Total, serious adverse events	0 / 0